Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Jul;31(7):1014–1016. doi: 10.1128/aac.31.7.1014

Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.

C W Stratton 1, C Liu 1, H B Ratner 1, L S Weeks 1
PMCID: PMC174863  PMID: 2821883

Abstract

This study used kill-kinetic methods to provide data on the bactericidal activity of subinhibitory (1/2 X MIC), inhibitory (1 x MIC), and suprainhibitory (4X, 6X, and 8X MIC) concentrations of deptomycin (LY146032) against strains of enterococci compared with those of ciprofloxacin, vancomycin, and ampicillin. Deptomycin was the most active agent tested, as determined by broth microdilution methods, with all strains being inhibited at concentrations less than or equal to 2 micrograms/ml. The kill-kinetic demonstrated that deptomycin had greater activity at all concentrations tested than the other cell wall-active agents; regrowth was seen, however, at lower concentrations. At higher concentrations (6X and 8X MIC), all agents tested demonstrated the same or less bactericidal activity than at 4X MIC, presumably due to the Eagle effect. Nevertheless, these results suggest that further evaluation of deptomycin as a therapeutic agent for serious enterococcal infections is warranted.

Full text

PDF
1015

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Eliopoulos G. M., Thauvin C., Gerson B., Moellering R. C., Jr In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1985 Mar;27(3):357–362. doi: 10.1128/aac.27.3.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eliopoulos G. M., Willey S., Reiszner E., Spitzer P. G., Caputo G., Moellering R. C., Jr In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986 Oct;30(4):532–535. doi: 10.1128/aac.30.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fass R. J., Helsel V. L. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1986 Nov;30(5):781–784. doi: 10.1128/aac.30.5.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Herzstein J., Ryan J. L., Mangi R. J., Greco T. P., Andriole V. T. Optimal therapy for enterococcal endocarditis. Am J Med. 1984 Feb;76(2):186–191. doi: 10.1016/0002-9343(84)90772-1. [DOI] [PubMed] [Google Scholar]
  5. Krogstad D. J., Pargwette A. R. Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrob Agents Chemother. 1980 Jun;17(6):965–968. doi: 10.1128/aac.17.6.965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lowes J. A., Hamer J., Williams G., Houang E., Tabaqchali S., Shaw E. J., Hill I. M., Rees G. M. 10 Years of infective endocarditis at St. Bartholomew's Hospital: analysis of clinical features and treatment in relation to prognosis and mortality. Lancet. 1980 Jan 19;1(8160):133–136. doi: 10.1016/s0140-6736(80)90614-5. [DOI] [PubMed] [Google Scholar]
  7. Malone D. A., Wagner R. A., Myers J. P., Watanakunakorn C. Enterococcal bacteremia in two large community teaching hospitals. Am J Med. 1986 Oct;81(4):601–606. doi: 10.1016/0002-9343(86)90544-9. [DOI] [PubMed] [Google Scholar]
  8. Mandell G. L., Kaye D., Levison M. E., Hook E. W. Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center. Arch Intern Med. 1970 Feb;125(2):258–264. doi: 10.1001/archinte.125.2.258. [DOI] [PubMed] [Google Scholar]
  9. Mederski-Samoraj B. D., Murray B. E. High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis. 1983 Apr;147(4):751–757. doi: 10.1093/infdis/147.4.751. [DOI] [PubMed] [Google Scholar]
  10. Murray B. E., Mederski-Samaroj B. Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest. 1983 Sep;72(3):1168–1171. doi: 10.1172/JCI111042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sande M. A., Scheld W. M. Combination antibiotic therapy of bacterial endocarditis. Ann Intern Med. 1980 Mar;92(3):390–395. doi: 10.7326/0003-4819-92-3-390. [DOI] [PubMed] [Google Scholar]
  12. Storch G. A., Krogstad D. J. Antibiotic-induced lysis of enterococci. J Clin Invest. 1981 Sep;68(3):639–645. doi: 10.1172/JCI110298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wilkowske C. J. Enterococcal endocarditis. Mayo Clin Proc. 1982 Feb;57(2):101–105. [PubMed] [Google Scholar]
  14. Wilson W. R., Geraci J. E. Antibiotic treatment of infective endocarditis. Annu Rev Med. 1983;34:413–427. doi: 10.1146/annurev.me.34.020183.002213. [DOI] [PubMed] [Google Scholar]
  15. Wilson W. R., Wilkowske C. J., Wright A. J., Sande M. A., Geraci J. E. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med. 1984 Jun;100(6):816–823. doi: 10.7326/0003-4819-100-6-816. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES